Chemistry:Arpraziquantel
-Praziquantel.svg) | |
| Clinical data | |
|---|---|
| Other names | (R)-Praziquantel |
| Drug class | Anthelmintic |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C19H24N2O2 |
| Molar mass | 312.413 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, a medication which is under investigation for the treatment of schistosomiasis in young children with less side effects than the racemate.[1]
Society and culture
Legal status
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children.[1] The applicant for this medicinal product is Merck Europe B.V.[1] It is intended exclusively for markets outside the European Union.[1]
Names
Arpraziquantel is the International nonproprietary name.[2]
References
- ↑ 1.0 1.1 1.2 1.3 "Arpraziquantel". 14 December 2023. https://www.ema.europa.eu/en/opinion-medicine-use-outside-EU/human/arpraziquantel. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information 34 (1). 2020.
Further reading
- "Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models". PLOS Neglected Tropical Diseases 14 (9): e0008649. September 2020. doi:10.1371/journal.pntd.0008649. PMID 32976496.
 |  |
